AMG-337 is under clinical development by NantPharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AMG-337’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AMG-337 overview

AMG-337 is under development for the treatment of solid tumors. It is a small molecule administered orally in the form of a capsule. It acts by targeting c-Met. It was also under development for the treatment of hepatocellular carcinoma, clear cell sarcoma, advanced or metastatic gastric cancer and gastroesophageal junction, esophageal adenocarcinoma.

NantPharma overview

NantPharma operates in pharmaceutical and healthcare industry. It operates as a subsidiary of NantWorks LLC and is headquartered in United States.

For a complete picture of AMG-337’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.